Biotech Growth Trust Plc (LON:BIOG) has published its Annual Report for 2026, giving shareholders and prospective investors a clear overview of the Trust’s performance, strategy and portfolio positioning.
The dedicated Annual Report section on the company’s website provides quick and easy access to key parts of the report, allowing readers to navigate directly to the areas most relevant to them.
Visitors can use the page to explore sections including Financial Highlights, the Portfolio Manager’s Review, KPIs, Historic Performance, the Chair’s Statement and Downloads.
The Portfolio Manager’s Review highlights the continued opportunity across the biotechnology sector.
“Despite the strong performance of the Company during the year, we believe we are still in the early stages of a sustained recovery. Many of the macroeconomic and political overhangs that weighed on the sector in the early part of the year have been resolved. Scientific innovation fuelling medical advancements remains robust. Biotechnology companies continue to develop first-in-class drugs addressing unmet medical needs.”
Geoff Hsu & Josh Golomb,
OrbiMed Capital LLC, Portfolio Manager
The Chair’s Statement also points to the strength of the Trust’s performance drivers during the year.
“The Board is encouraged by the breadth and quality of the drivers underpinning the Company’s performance during the year, with returns led in particular by strong contributions from small and mid-capitalisation biotechnology companies. While we remain mindful of the inherent volatility of both the sector and the Company’s active approach, it is reassuring to see the portfolio respond strongly as conditions improved and investment theses were realised.”
Roger Yates,
Chair
For quick access to the different sections of the 2026 Annual Report, visit the Biotech Growth Trust Annual Report page here:
www.biotechgt.com/corporate-information/annual-report-2026
Biotech Growth Trust Plc is an investment trust focused on biotechnology companies, aiming to deliver long-term capital growth by investing in businesses developing medical treatments and healthcare innovations.
